EP2350263A4 - Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp) - Google Patents

Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Info

Publication number: EP2350263A4
Authority: EP; European Patent Office
Prior art keywords: tslp; compositions; methods; mediated conditions; thymic stromal
Prior art date: 2008-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP09822721.8A

Other languages

German (de)

English (en)

Other versions

EP2350263A1 (fr

Inventor

Richard L Watson

Anthony B Wood

Gregory J Archambeau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Microdiffusion Inc

Original Assignee

Microdiffusion Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-22

Filing date

2009-10-22

Publication date

2013-07-03

2008-10-24 Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en

2009-10-22 Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc

2011-08-03 Publication of EP2350263A1 publication Critical patent/EP2350263A1/fr

2013-07-03 Publication of EP2350263A4 publication Critical patent/EP2350263A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Dispersion Chemistry (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)

EP09822721.8A 2008-10-22 2009-10-22 Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp) Withdrawn EP2350263A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10745308P	2008-10-22	2008-10-22
US10748008P	2008-10-22	2008-10-22
US12/258,210 US20090274730A1 (en)	2007-10-25	2008-10-24	Compositions and methods for treating inflammation
PCT/US2009/061710 WO2010048425A1 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Publications (2)

Publication Number	Publication Date
EP2350263A1 EP2350263A1 (fr)	2011-08-03
EP2350263A4 true EP2350263A4 (fr)	2013-07-03

Family

ID=42119683

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP09822743.2A Withdrawn EP2364154A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
EP09822721.8A Withdrawn EP2350263A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP09822743.2A Withdrawn EP2364154A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)

Country Status (9)

Country	Link
EP (2)	EP2364154A4 (fr)
JP (4)	JP5688370B2 (fr)
CN (2)	CN102256607B (fr)
AU (2)	AU2009308362B2 (fr)
BR (2)	BRPI0920430A2 (fr)
CA (2)	CA2741341A1 (fr)
IL (2)	IL212277A0 (fr)
MX (2)	MX337035B (fr)
WO (2)	WO2010048455A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6702949B2 (en)	1997-10-24	2004-03-09	Microdiffusion, Inc.	Diffuser/emulsifier for aquaculture applications
JP5306214B2 (ja)	2006-10-25	2013-10-02	リバルシオコーポレイション	混合装置
EP2097107B1 (fr)	2006-10-25	2016-05-04	Revalesio Corporation	Traitement thérapeutique des yeux à l'aide d'une solution enrichie en oxygène
US8445546B2 (en)	2006-10-25	2013-05-21	Revalesio Corporation	Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9523090B2 (en)	2007-10-25	2016-12-20	Revalesio Corporation	Compositions and methods for treating inflammation
US9745567B2 (en)	2008-04-28	2017-08-29	Revalesio Corporation	Compositions and methods for treating multiple sclerosis
US10125359B2 (en)	2007-10-25	2018-11-13	Revalesio Corporation	Compositions and methods for treating inflammation
MX337862B (es) *	2008-04-28	2016-03-16	Revalesio Corp	Composiciones y métodos para el tratamiento de la esclerosis multiple.
CN102076327B (zh)	2008-05-01	2014-04-16	利发利希奥公司	治疗消化功能紊乱的组合物和方法
US8815292B2 (en)	2009-04-27	2014-08-26	Revalesio Corporation	Compositions and methods for treating insulin resistance and diabetes mellitus
SG185133A1 (en)	2010-05-07	2012-12-28	Revalesio Corp	Compositions and methods for enhancing physiological performance and recovery time
MX2013001636A (es)	2010-08-12	2013-05-01	Revalesio Corp	Composiciones y metodos para el tratamiento de taupatias
MX2013011888A (es) *	2011-04-13	2014-02-27	Revalesio Corp	Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria.
CN102250213B (zh) *	2011-07-01	2012-11-07	中国药科大学	基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268069B (zh) *	2011-07-01	2012-11-28	中国药科大学	基质金属蛋白酶-9多肽抑制剂4及其应用
CN102268070B (zh) *	2011-07-01	2012-11-28	中国药科大学	基质金属蛋白酶-9多肽抑制剂2及其应用
KR101492435B1 (ko) *	2012-12-28	2015-02-10	고려대학교 산학협력단	ＨＩＦ１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
CN105477628B (zh) *	2014-09-19	2021-04-30	山东蓝金生物工程有限公司	抗癌组合物及其用途
CN106943593A (zh) *	2017-03-24	2017-07-14	浙江中医药大学	抗tslp抗体在制备防治慢性瘙痒药物中的应用
EP3645035A4 (fr) *	2017-06-27	2021-04-07	Translational Sciences, Inc.	Inhibition de la métalloprotéinase matricielle 9 vasculaire pour traiter une lésion ischémique
AU2020279960A1 (en) *	2019-05-17	2021-12-23	The Trustees Of The University Of Pennsylvania	Methods and compositions for treating obesity and/or skin disorders
CN112876564B (zh) *	2019-11-29	2022-07-15	康诺亚生物医药科技（成都）有限公司	一种tslp相关病症治疗剂的开发和应用
WO2025076280A1 (fr)	2023-10-05	2025-04-10	Ashibio, Inc.	Méthodes et compositions de traitement de troubles médiés par la mmp-9

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030232114A1 (en) *	2002-06-13	2003-12-18	Nikola Dekleva	Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) *	2002-09-09	2004-03-18	Borsos Ferenc	Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
WO2008018932A2 (fr) *	2006-05-01	2008-02-14	The Board Of Trustees Of The Leland Stanford Junior University	Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion
WO2008052143A2 (fr) *	2006-10-25	2008-05-02	Revalesio Corporation	Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4657450B2 (ja) *	1998-07-28	2011-03-23	ザリージェンツオブザユニバーシティオブカリフォルニア	感覚伝達に関与するｇタンパク質共役レセプターをコードする核酸
EP2322226A3 (fr) *	1999-07-21	2011-08-17	Omeros Corporation	Solutions et procédés pour l'inhibition de la douleur, la inflammation et la degradation du cartilage
US20040235732A1 (en) *	2000-11-03	2004-11-25	Qun-Yong Zhou	Method for modulating angiogenesis using prokineticin receptor antagonists
US20070077553A1 (en) *	2003-10-30	2007-04-05	Rosetta Genomics	Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
WO2004071436A2 (fr) *	2003-02-10	2004-08-26	Thomas Jefferson University	Utilisation de ligands gcc
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) *	2004-01-06	2008-07-01	Franco Vitaliano	Smart bio-nanoparticle elements
KR100583430B1 (ko) *	2004-03-08	2006-05-24	양경숙	차륜 가변형 스쿠터
US20050249712A1 (en) *	2004-03-23	2005-11-10	The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Methods for use of TSLP and agonists and antagonists thereof
US20080014247A1 (en) *	2006-06-30	2008-01-17	Nucryst Pharmaceuticals	Metal-containing formulations and methods of use
AU2007349224B2 (en) *	2006-10-25	2014-04-03	Revalesio Corporation	Methods of wound care and treatment
EP2097107B1 (fr) *	2006-10-25	2016-05-04	Revalesio Corporation	Traitement thérapeutique des yeux à l'aide d'une solution enrichie en oxygène
MX337862B (es) *	2008-04-28	2016-03-16	Revalesio Corp	Composiciones y métodos para el tratamiento de la esclerosis multiple.

2009
- 2009-10-22 EP EP09822743.2A patent/EP2364154A4/fr not_active Withdrawn
- 2009-10-22 WO PCT/US2009/061744 patent/WO2010048455A1/fr not_active Ceased
- 2009-10-22 MX MX2011004235A patent/MX337035B/es active IP Right Grant
- 2009-10-22 WO PCT/US2009/061710 patent/WO2010048425A1/fr not_active Ceased
- 2009-10-22 MX MX2011004233A patent/MX2011004233A/es active IP Right Grant
- 2009-10-22 BR BRPI0920430A patent/BRPI0920430A2/pt not_active IP Right Cessation
- 2009-10-22 EP EP09822721.8A patent/EP2350263A4/fr not_active Withdrawn
- 2009-10-22 CA CA2741341A patent/CA2741341A1/fr active Pending
- 2009-10-22 CN CN200980151711.6A patent/CN102256607B/zh not_active Expired - Fee Related
- 2009-10-22 BR BRPI0920201A patent/BRPI0920201A2/pt not_active IP Right Cessation
- 2009-10-22 AU AU2009308362A patent/AU2009308362B2/en not_active Ceased
- 2009-10-22 CA CA2741336A patent/CA2741336A1/fr not_active Abandoned
- 2009-10-22 CN CN200980151710.1A patent/CN102257130B/zh not_active Expired - Fee Related
- 2009-10-22 AU AU2009308302A patent/AU2009308302B2/en not_active Ceased
- 2009-10-22 JP JP2011533341A patent/JP5688370B2/ja not_active Expired - Fee Related
- 2009-10-22 JP JP2011533355A patent/JP5688371B2/ja not_active Expired - Fee Related
2011
- 2011-04-12 IL IL212277A patent/IL212277A0/en unknown
- 2011-04-13 IL IL212309A patent/IL212309A/en not_active IP Right Cessation
2014
- 2014-12-05 JP JP2014246760A patent/JP2015044869A/ja not_active Withdrawn
- 2014-12-05 JP JP2014246753A patent/JP2015044868A/ja not_active Withdrawn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030232114A1 (en) *	2002-06-13	2003-12-18	Nikola Dekleva	Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) *	2002-09-09	2004-03-18	Borsos Ferenc	Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
WO2008018932A2 (fr) *	2006-05-01	2008-02-14	The Board Of Trustees Of The Leland Stanford Junior University	Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion
WO2008052143A2 (fr) *	2006-10-25	2008-05-02	Revalesio Corporation	Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010048425A1 *

Also Published As

Publication number	Publication date
JP2012506451A (ja)	2012-03-15
BRPI0920430A2 (pt)	2019-09-24
EP2364154A1 (fr)	2011-09-14
JP2012506453A (ja)	2012-03-15
WO2010048455A1 (fr)	2010-04-29
JP2015044869A (ja)	2015-03-12
JP5688371B2 (ja)	2015-03-25
CN102256607B (zh)	2014-11-05
CA2741336A1 (fr)	2010-04-29
AU2009308302A1 (en)	2010-04-29
AU2009308362B2 (en)	2016-02-04
MX337035B (es)	2016-02-09
CN102257130A (zh)	2011-11-23
WO2010048425A1 (fr)	2010-04-29
MX2011004233A (es)	2011-06-24
IL212309A0 (en)	2011-06-30
CN102256607A (zh)	2011-11-23
BRPI0920201A2 (pt)	2019-09-10
JP5688370B2 (ja)	2015-03-25
JP2015044868A (ja)	2015-03-12
CA2741341A1 (fr)	2010-04-29
EP2350263A1 (fr)	2011-08-03
AU2009308362A1 (en)	2010-04-29
EP2364154A4 (fr)	2013-07-10
MX2011004235A (es)	2011-06-24
IL212277A0 (en)	2011-06-30
IL212309A (en)	2016-04-21
CN102257130B (zh)	2016-07-06
AU2009308302B2 (en)	2016-01-21

Publication	Publication Date	Title
EP2350263A4 (fr)	2013-07-03	Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)
HRP20190214T1 (hr)	2019-03-22	Pripravci i metode za liječenje purpure
EP2334804A4 (fr)	2012-05-23	Compositions et procédés pour co-culture
PT3190128T (pt)	2019-02-07	Composições e métodos para tratar distúrbios mediados pela ige
IL208284A0 (en)	2010-12-30	Compositions and methods for preparing and using same
ZA201202923B (en)	2013-06-26	Methods and compositions for modulating tau levels
ZA201203603B (en)	2016-01-27	Lyophilization methods, compositions, and kits
IL210153A0 (en)	2011-03-31	Nutrigenomics methods and compositions
GB0815872D0 (en)	2008-10-08	Novel method and compositions
IL214798A0 (en)	2011-11-30	Methods and compositions for stem cell cultures
GB0819530D0 (en)	2008-12-03	Methods and compositions
IL210559A0 (en)	2011-03-31	Novel compositions and methods
ZA201007165B (en)	2011-12-28	Composition and system for turf maintenance
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
IL208445A0 (en)	2010-12-30	Compositions and methods for immunotherapy
SG10201505149WA (en)	2015-07-30	Novel compositions and methods
EP2294199A4 (fr)	2011-06-15	Compositions et procédés pour améliorer des plantes
GB0817585D0 (en)	2008-11-05	Novel compositions and methods
EP2294198A4 (fr)	2011-10-19	Procédés et compositions permettant d'améliorer des plantes
GB0811250D0 (en)	2008-07-30	Methods and compositions
GB0811152D0 (en)	2008-07-23	Methods and compositions
GB0816534D0 (en)	2008-10-15	Compositions and methods
GB0818399D0 (en)	2008-11-12	Methods and compositions
GB0803464D0 (en)	2008-04-02	Methods and compositions

Legal Events

Date	Code	Title	Description
2011-07-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-08-03	17P	Request for examination filed	Effective date: 20110520
2011-08-03	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2011-08-10	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: REVALESIO CORPORATION
2012-01-25	DAX	Request for extension of the european patent (deleted)
2013-07-03	A4	Supplementary search report drawn up and despatched	Effective date: 20130531
2013-07-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/573 20060101ALI20130524BHEP Ipc: A61K 9/00 20060101AFI20130524BHEP Ipc: A61K 33/00 20060101ALI20130524BHEP
2014-09-24	17Q	First examination report despatched	Effective date: 20140826
2017-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-10-04	18D	Application deemed to be withdrawn	Effective date: 20170503